Latest News - Page 3 of 52 - Oklahoma Society of Clinical Oncology

On September 25, 2024, TAGRISSO® (osimertinib) was approved for the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. For your reference, attached […]

Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) and no known epidermal […]

Nursing Statistics and Trends You Need to Know: https://www.registerednursing.org/articles/50-nursing-statistics/

Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy has been approved in the US for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).1 Additional information on the approval can be found in the press release below. https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-the-us-for-endometrial-cancer.html

Based on three Phase II trials of AstraZeneca and Daiichi Sankyo’s Enhertu which showed clinically meaningful responses across a broad range of tumours Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of […]

Imfinzi plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial Longest survival follow-up ever reported for immunotherapy treatment in this setting  Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall […]

OSCO’s recent presentation of the Official Review of the San Antonio Breast Cancer Symposium provided attendees with excellent updates on many breast cancer topics.  The first session was presented by Joyce O’Shaughnessy, MD on HR+ Breast Cancer.  The second session was a Radiation Oncology Update presented by Danushka Seneviratne, MD, PhD.  After a short break […]

Pfizer Oncology is proud to announce the FDA approval of a new pediatric indication for BESPONSA® (inotuzumab ozogamicin). The following information is available for review: ·       Full Prescribing Information Including Boxed Warning

AstraZeneca’s TAGRISSO® (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The approval following a Priority Review by the Food and Drug Administration (FDA) was based on the results from the FLAURA2 Phase III trial […]

The Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection effective for dates of service on or after April 1, 2024 J1323- Injection, elranatamab-bcmm, 1 mg Please see full prescribing information including Boxed Warning, HERE.